Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin

Figure 1 Tumor volumes at different time-points in Hepal-6 (A) and H22 (B) models. Cont-Ab: mice transfused with control antibodies; Cont-NS: mice transfused with NS; anti-mAb: mice transfused with anti-endoglin mAb. ^aP < 0.05, ^bP < 0.01. Data are shown as mean ± SD, n = 10 in each group.

Figure 2 The survival rates at different time-points in Hepal-6 (A) and H22 (B) models. Log-rank test, P < 0.01, n = 10 in each group.

Figure 3 Significant decrease in microvessel density (stained as purple color) in the tumor tissues from the mice transfused with anti-endoglin mAb (A) compared to the mice transfused with control antibodies (B) and the mice transfused with NS (C). Quantitative analysis of microvessels in Hepal-6 and H22 models (D), the bars represent mean ± SD, ^bP < 0.001.

Figure 4 Significant inhibition of angiogenesis in the tumor cell-encapsulated beads from the mice transfused with anti-endoglin mAb (A) than that in the tumor tissues from the mice transfused with control antibodies (B) and the mice transfused with NS (C). Quantitative determination of FITC-dextran uptake in Hepal-6 and H22 models (D); the bars represent mean ± SD, ^bP < 0.001.

Figure 5 Significantly increased apoptosis in the tumor tissues from the mice transfused with anti-endoglin mAb (A) compared to the mice transfused with control antibodies (B) and the mice transfused with NS (C). Quantitative analysis of apoptotic cells in Hepal-6 and H22 models (D), the bars represent mean ± SD, ^bP < 0.001.